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Background: The development of allergic sensitization and allergic disease may be related to factors during
intrauterine life, but the role of maternal preeclampsia is not known.
We studied if maternal preeclampsia is associated with long-term allergic sensitization, allergic rhinoconjunctivitis,
atopic dermatitis, asthma and with altered lung function in late childhood.
Methods: 617 children participated in a 1:2 matched and controlled historical cohort study; 230 born after
preeclamptic pregnancies and 387 born after normotensive pregnancies. Specific IgE in serum and lung function
were measured at the age of 12.8 years and questionnaires on maternal and adolescent data were completed at
the ages of 10.8 years (girls) and 11.8 years (boys), and at 12.8 years (both genders). The association between birth
after preeclampsia and the main outcome measures allergic sensitization, allergic rhinoconjunctivitis, atopic
dermatitis, asthma and lung function in late childhood were analysed with multiple regression analyses, including
possible confounders.
Results: Severe maternal preeclampsia was associated with high level allergic sensitization (sum of specific IgE in
serum ≥ 3.9 kU/l; the 25 percentile for all children being sensitized); odds ratio (OR): 3.79; 95% confidence interval
(CI): (1.54, 9.32); p = 0.015 and with allergic rhinoconjunctivitis in offspring; OR: 2.22, 95% CI: (1.19, 4.14), p = 0.047.
Preeclampsia was not associated with atopic dermatitis, asthma or altered lung function in late childhood.
Conclusion: Maternal preeclampsia was associated with allergic sensitization and allergic rhinoconjunctivitis in
offspring in late childhood, but not with other atopic diseases.
Keywords: Childhood, Allergy, Allergic rhinoconjunctivitis, Allergic sensitization, Asthma, Atopic dermatitis, Atopy,
Child, Lung function, PreeclampsiaBackground
The prevalence of allergy and asthma has been increas-
ing in both adults and children during the last decades
[1]. There is also increasing evidence that early life
events including intrauterine factors are important for
the development of atopic disease [2-4].
Atopic diseases are associated with an inhibition of the
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reproduction in any medium, provided the or(Th1)/Th2 balance after birth, resulting in Th2 cytokine
predominance [4,5]. Maternal inflammatory cytokines
during pregnancy have been shown to correlate with
corresponding cytokines in offspring at the age of one
[6], and an association between an altered maternal
cytokine profile and subsequent atopic disease in off-
spring has been suggested [7].
Preeclampsia is a common and potentially serious com-
plication of the second half of pregnancy affecting both
mother and child, characterised by maternal hypertension
and proteinuria, and occasionally foetal growth restriction
[8,9]. Preeclampsia is associated with an increase inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ternal immune response towards an increased Th1/Th2
balance [10]. This could potentially skew the child’s cyto-
kine balance after birth in the same direction, and thereby
protect against the development of atopic disease [6].
However, clinical studies have suggested that complica-
tions during pregnancy may rather increase the risk of
childhood asthma and allergic rhinoconjunctivitis [11,12],
and an association between maternal preeclampsia and
subsequent allergic sensitization in offspring during ado-
lescence has been suggested [13].
Preeclampsia has also been associated with an in-
creased risk of RDS and BPD in preterm infants and to
recurrent wheezing in a general population of pre-
school children [14]. This association might either be
due to an increased soluble antiangiogenic factor [15], or
a congenital reduction in airways calibre and compliance
in particular in infants with intrauterine growth restric-
tion [16]. However, no studies have evaluated a possible
long-term association between maternal preeclampsia
and asthma or lung function in offspring.
In a long–term follow-up of children of preeclamptic
and normal pregnancies, the aim was to study if mater-
nal preeclampsia is associated with allergic sensitization,
allergic rhinoconjunctivitis, atopic dermatitis, asthma,
and lung function in late childhood.Methods
Study population and design
The study was a part of “the Stavanger study” described
in detail elsewhere [17]. In short, cord blood was drawn
from all newborns at Stavanger University Hospital dur-
ing 1993–1995, during which 12 804 deliveries took
place. The Medical Birth Registry of Norway was used toPreeclampsia
(boys/girls)
FU 2
Participants
n = 183 (50%)
(96 (54%) / 87 (46%))
n = 366
(178/188)
Participants
n = 230 (63%)
(109 (61%) / 121 (64%))
FU 1
Invited
participants
Missing
n = 136 (37%)
(69 (39%) / 67 (36%))
Missing
n = 183 (50%)
(82 (46%) / 101 (54%))
n=179
Figure 1 Number of participants invited to the Stavanger study, and
Abbreviations: FU1 = First follow-up at the ages of 10.8 years (girls) and 11.8
genders); Preeclampsia = children born after pregnancies with preeclampsiaidentify offspring exposed to maternal preeclampsia and
unexposed offspring, and information was verified and
supplemented with data from hospital records. All off-
spring of preeclamptic pregnancies were defined as ex-
posed. For each exposed, two matched unexposed
offspring were selected as follows: one was defined as
the next delivery in the hospital and one as the next
delivery matched on maternal age. Exposed and unex-
posed offspring were invited to participate in a follow-
up (FU) study at the target ages of 10.8 years (girls)
and 11.8 years (boys) (FU1), and a second follow-up at
the target age of 12.8 years (FU2) (Figure 1). The target
ages at FU1 were selected to also be able to collect pu-
berty stage data at an age presumed to represent the
start of puberty development in the children [17]. If
unexposed offspring did not respond, no substitutes
were invited. Consequently, the study design was a his-
torically matched cohort with 1025 children; 366 in
the preeclampsia cohort and 659 in the control cohort.
The study was approved by the Norwegian Data In-
spectorate, the Regional Committee for Ethics in medical
research and the Institutional Review Board of the Na-
tional Cancer Institute of the United States. Written
consent was obtained from all participating children and
mothers at follow-up.Data collection and definitions
Preeclampsia was defined as a diastolic blood pres-
sure increased by ≥ 25 mmHg to a persistent pressure
of ≥ 90 mmHg and proteinuria with dipstick ≥ +1 present
in at least one urine sample after 20 weeks of gestation.
Preeclampsia was further divided into mild, moderate and
severe. Moderate preeclampsia was defined as proteinuria
with dipstick ≥ +2. Severe preeclampsia was defined asParticipants
n = 287 (44%)
(136 (40%) / 151 (47%))
n = 659
(338/321)
Participants
n = 387 (59%)
(187 (55%) / 200 (62%))
Normal
(boys/girls)
Missing
n = 230 (63%)
(109 (61%) / 121 (64%))
Missing
n = 372 (56%)
(202 (60%) / 170 (53%))
n=279
numbers that consented to first and second follow-up.
years (boys); FU2 = Second follow-up at the age of 12.8 years (both
; Normal = children born after pregnancies without preeclampsia.
Byberg et al. BMC Pediatrics 2014, 14:101 Page 3 of 8
http://www.biomedcentral.com/1471-2431/14/101proteinuria with dipstick ≥ + 3 and diastolic blood pres-
sure of ≥110 mmHg.
Maternal body mass index (BMI, kg/m2) was calcu-
lated using weight measurement at the first antenatal
visit at primary healthcare examination during the first
trimester of pregnancy and height measurement from
FU1. Maternal smoking in pregnancy was recorded at
the same antenatal visit. Data on gestational age at birth
and mode of delivery were extracted from hospital re-
cords. Birth weight for gestational age was calculated as
z-scores based on Scandinavian normal standards [18].
Weight and height in offspring were recorded at FU1,
and z-scores for BMI were calculated using the latest
growth references for Norwegian children [19].Questionnaires
At FU1, the questions included the birth order of the
child, parental asthma, and atopic disease of the child.
The mothers were asked as follows: Has your child ever
had asthma (diagnosed by physician), allergy in nose/
eyes (hay fever) or atopic dermatitis (childhood eczema)?
At FU2, the children answered a questionnaire from the
International Study of Asthma and Allergies in Childhood
(ISAAC) translated into Norwegian [20]. Reported asthma
symptoms and asthma medication during the last year
and asthma diagnosis ever were recorded. Missing an-
swers were interpreted as negative. Current asthma at
FU2 was defined as asthma ever, in addition to asthma
symptoms or the use of asthma medication during the last
12 months.Laboratory methods
At FU2 blood was drawn from the children, centrifuged
and aliquoted, and serum stored at -80°C. Allergic
sensitization was determined by serum specific immuno-
globulin E (IgE) antibodies using Phadiatop® and fx5E®
(ImmunoCAP® 250, Phadia AB, Uppsala, Sweden). If
Phadiatop® was positive, serum was further analysed for
specific IgE against Dermatophagoides pteronyssinus, cat,
horse, dog, timothy, common silver birch, mugwort and
Cladosporium herbarum. If fx5E® was positive, serum
was further analysed for specific IgE against egg white,
milk, fish (cod), wheat, peanut and soya bean. Allergic
sensitization was defined as specific IgE ≥ 0.35 kU/l for
at least one allergen. The levels of specific IgE ≥ 0.35
were added together, and high level allergic sensitization
was defined as a sum > 3.9 kU/l; the 25 percentile for all
children being sensitized.
At FU2, lung function measures were performed by
spirometry according to standard quality criteria [21]
with a Vmax Encore spirometer (Sensor Medics Inc.,
Anaheim, USA).Statistics
Groups were compared with Pearson’s chi-square exact
test for the dichotomous outcomes and independent t-
tests (Gosset’s t-test) and one way analysis of variance
for the continuous outcomes. Bonferroni-correction of
p-values was applied to adjust for multiple testing.
Before analyses, the variable preeclampsia was cate-
gorised into none, mild/moderate (combined) and se-
vere. Risk associations between preeclampsia and related
pregnancy variables with outcomes in late childhood
were analysed by multiple logistic and linear regression
analyses, including the covariates gender, birthweight
z-score for gestational age, being firstborn, maternal
smoking during pregnancy, maternal age at birth, cae-
sarean section, gestational age, maternal BMI and ma-
ternal asthma. Paternal asthma was not included as a
covariate due to low response rate. Each variable was
first entered separately into simple regression models.
Covariates significant at the 10% level and those con-
sidered important were included in backward stepwise
logistic and linear regression analyses. Final models in-
cluded the remaining covariates significant at the 5%
level and the covariates gender and maternal asthma,
considered as biologically important. Analysing the or-
dinal variable preeclampsia as were it a continuous
variable with scores 0, 1 and 2 for the three levels, ORs
showing a trend have been calculated by multiple lo-
gistic regression analysis.
From logistic regression odds ratios (OR) with 95% con-
fidence interval (CI) and likelihood ratio p-value (LR-p) for
each exposure are reported. From linear regression the es-
timated coefficients (b), 95% CI and F-test p-value are re-
ported. Interactions between preeclampsia and all other
risk factors remaining in the final models were tested. Also
interactions between preeclampsia and gender were tested.
All tests were 2-tailed and p-values ≤ 0.05 were consid-
ered statistically significant. Due to missing data, match-
ing was not included in the analyses, but the matching
variables were adjusted for. SPSS for Windows (version
18.0.0, Chicago, Ill., USA) was used for all analyses.
Results
Characteristics of the participants
The number of children invited and participating in FU1
and FU2 are shown in Figure 1. Table 1 shows the char-
acteristics of children who consented to FU1, and those
who did not consent. There were no significant differ-
ences in perinatal characteristics of children who con-
sented and those who did not consent.
At FU1, the age of the girls was 10.8 (±0.22) years
(mean, SD), and for boys 11.8 (±0.18) years. At FU2 the
age for both genders was 12.8 (±0.19) years.
BMI z-score at FU1 was higher in children who only
consented to FU1 than in children who consented to both
Table 1 Initial characteristics of 1025 Norwegian children born in 1993–1995 and invited to the Stavanger study
according to consenting or not to the first follow-up 11–12 years latera)
Consented (n = 617) Did not consent (n = 409)
Variable n n p
Gender: boys, n (%) 617 296 (48.0) 408 220 (53.9) 0.065b)
Preeclampsia, n (%) 617 230 (37.3) 409 137 (33.5) 0.231b)
Maternal age, years, mean, 95% CI 610 28.0 (27.7, 28.4) 408 27.6 (27.2, 28.1) 0.194c)
Gestational age, weeks; mean, 95% CI 604 39.3 (39.1, 39.5) 343 39.2 (39.0, 39.5) 0.855c)
Birth weight z-scored) 590 −0.17 (−0.27, −0.07) 339 −0.06 (−0.18, 0.06) 0.169c)
Abbreviations: CI confidence interval.
a)Follow-up at the ages of 10.8 years (girls) and 11.8 years (boys);
b)Exact chi-square test;
c)Gosset’s t-test;
d)Number of standard deviations from mean.
Byberg et al. BMC Pediatrics 2014, 14:101 Page 4 of 8
http://www.biomedcentral.com/1471-2431/14/101FU1 and FU2 (mean difference BMI z-score: 0.31 kg/
m2; 95% CI: 0.13 to 0.49; p = 0.001). When analysed
separately for girls and boys, the difference persisted
for girls only (mean difference BMI: 0.44 kg/m2; 95%
CI: 0.20 to 0.68; p < 0.001). More children had atopic
dermatitis of those who only consented to FU1 (48/
150; 32%), than those who consented to both FU1 and
FU2 (100/445; 22.5%); p = 0.022. No other variables
differed significantly between those who consented to
FU1 only and those who consented to both FU1 and
FU2.Table 2 Atopy, asthma and lung function in late childhood in 58
status
Severe
preeclampsia
Mild/moderate
preeclampsia
Outcome variable n n
FU1 variables
Allergic rhinoconjunctivitis,
n (%)
54 19 (35.2) 161 36 (22.4)
Atopic dermatitis, n (%) 54 15 (27.8) 163 37 (22.7)
Asthma, n (%) 53 9 (17.0) 161 14 (8.7)
FU2 variables
Allergic sensitization,
n (%)
39 15 (38.5) 112 40 (36.3)
High level allergic
sensitization, n (%)c)
39 15 (38.5) 112 28 (25.0)
Current asthma, n (%) 46 6 (13.0) 123 12 (9.8)
FEV1%, mean, 95% CI 45 89.7 (87.0, 92.5) 126 91.0 (89.0, 93.0)
FVC%, mean, 95% CI 45 99.2 (95.5, 102.8) 126 100.0 (97.7, 102.3)
FEV1/FVC, mean, 95% CI 45 84.6 (82.7, 86.5) 126 85.3 (83.9, 86.6)
FEF25–75%, mean, 95% CI 45 84.9 (79.4, 90.3) 126 89.6 (85.9, 93.4)
FEF25–75/FVC, mean,
95% CI
45 54.5 (50.0, 59.0) 126 57.3 (54.7, 59.9)
Abbreviations: FU1 first follow-up at the ages of 10.8 years (girls) and 11.8 years (boys), F
expiratory volume in first second predicted, CI Confidence interval, FVC% forced vital c
forced vital capacity, predicted.
a)Pearson’s exact chi-square test (dichotomous variable) and one way analysis of variance
b)Cochran-Armitage test for dichotomous outcomes and one way analysis of variance for
c)Sum of specific IgE > 3.9 kU/l.Preeclampsia and outcomes
The outcome in children according to maternal pre-
eclampsia status is shown in Table 2. A greater proportion
of offspring from pregnancies with severe preeclampsia
had allergic rhinoconjunctivitis and high level allergic
sensitization than offspring from pregnancies with mild/
moderate or no preeclampsia.
Among children with any allergic sensitization, 50%
had symptoms of allergic rhinoconjunctivitis, whereas
5.6% of children with allergic rhinoconjunctivitis did not
have any allergic sensitization.6 Norwegian children according to mother’s preeclampsia
No preeclampsia Severe vs. no
preeclampsia
Mild/moderate
vs. no preeclampsia
Overall
n p-valuea) p-valuea) p-valueb)
371 71 (19.1) 0.018 0.822 0.015
369 92 (24.9) 1.476 1.172 1.000
366 30 (8.2) 0.092 1.730 0.100
230 72 (31.3) 0.918 0.924 0.296
230 50 (21.7) 0.056 1.166 0.042
279 19 (6.8) 0.454 0.630 0.126
272 91.1 (90.0, 92.2) 1.000 1.000 0.682
272 101.1 (99.8, 102.4) 0.965 1.000 0.489
272 84.9 (84.1, 85.7) 1.000 1.000 0.482
272 87.4 (85.1, 89.6) 1.000 0.827 0.317
272 55.7 (54.1, 57.4) 1.000 0.906 0.429
U2 second follow-up at the age of 12.8 years (both genders), FEV1% forced
apacity predicted, FEF25–75% forced expiratory flow between 25% and 75% of the
(continuous variable) with Bonferroni corrections;
continuous outcomes;
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preeclampsia was a risk factor for allergic rhinoconjunc-
tivitis; OR: 2.29; 95% CI: 1.24 to 4.24; LR-p = 0.036.
Table 3 shows the results of adjusted logistic regression
analyses with different atopic diseases as outcomes ac-
cording to maternal preeclampsia status. In fully ad-
justed analyses, severe preeclampsia was a significant
risk factor for high level allergic sensitization, but not so
for any other outcomes of atopic disease.
In the backward stepwise regression analysis of high
level allergic sensitization the final model included pre-
eclampsia as a significant risk factor, in addition to male
gender, maternal smoking during pregnancy, gestational
age in weeks and maternal asthma (Table 3). Specifically,
birth after severe preeclampsia gave 4.05 times higher
odds for high level allergic sensitization than birth after
non-preeclampsia, adjusted for the other variables.
In a backward stepwise regression analysis of allergic
rhinoconjunctivitis the final model included preeclamp-
sia in addition to male gender and maternal asthma
(Table 3). Specifically, severe preeclampsia gave 2.23
times higher odds for allergic rhinoconjunctivitis than
no preeclampsia, adjusted for the other variables.
Adjusted for the same covariates as in final analysis,
there was a trend of an increasing effect of preeclampsia
(none, mild/moderate, severe) on both high level allergic
sensitization (OR = 1.88; 95% CI: (1.23, 2.86); LR-p = 0.003)
and on allergic rhinoconjunctivitis (OR = 1.42; 95% CI:
(1.07, 1.89); LR-p = 0.018).
Preeclampsia was not a significant risk factor for other
outcomes of atopic disease in the final models.Table 3 Summary of logistic regression analyses of atopic disea
mother’s preeclampsia status
Effects of materna
Fully adjusteda)
n Mild/moderate
preeclampsia
Severe
preeclampsia
Outcome variable OR 95% CI OR 95% CI
FU1 variables
Allergic rhinoconjunctivitis 514 1.21 (0.70, 2.07) 2.10 (0.86, 5.11)
Atopic dermatitis 513 0.90 (0.54, 1.50) 0.97 (0.39, 2.39)
Asthma 506 0.87 (0.38, 1.97) 0.72 (0.19, 2.77)
FU2 variables
Allergic sensitization 329 1.49 (0.84, 2.63) 2.44 (0.93, 6.42)
High level allergic sensitizationc) 329 1.64 (0.87, 3.11) 4.42 (1.58, 12.3)
Current asthma 388 1.11 (0.45, 2.73) 0.69 (0.15, 3.18)
Abbreviations: OR Odds ratio, CI Confidence interval, FU1 first follow-up at the ages of 10.
(both genders); Likelihood-ratio-p refers to exposure only.
a)Adjusted for gender, birth weight z-score adjusted for gestational age, being firstborn, C
maternal age, maternal body mass index (kg/m2) and maternal asthma;
b)After backward stepwise selection from fully adjusted model with p≤ 0.05; all final anal
c)High level allergic sensitization = Sum of specific IgE > 3.9 kU/l; the 25 percentile of sens
d)Adjusted for gender, maternal smoking during pregnancy, gestational age in weeks anPreeclampsia was not a risk factor for any outcomes of
lung function in unadjusted or fully adjusted linear re-
gression analyses. Table 4 shows the results of linear re-
gression analyses of lung function variables according to
maternal preeclampsia status.
Discussion
In the present study we found positive associations be-
tween severe maternal preeclampsia and both high level
allergic sensitization and allergic rhinoconjunctivitis in
adolescent offspring. This is to our knowledge showed
for the first time. Preeclampsia was not associated with
subsequent atopic dermatitis, asthma or alterations in
lung function.
Preeclampsia and atopic disease
Few other studies have evaluated preeclampsia as a pos-
sible risk factor for subsequent allergic sensitization or
atopic disease in a long-term perspective. Keski-Nisula
et al. found an association between maternal preeclamp-
sia and severe atopy in children. However, in that study
only women who underwent caesarean section were in-
cluded, and a very high percentage of children were sen-
sitized [13]. Nafstad et al. found a relation between
uterus-related complications during pregnancy and aller-
gic rhinoconjunctivitis and asthma, but not for children
born after preeclamptic pregnancies [11]. To our know-
ledge, no other studies have evaluated the risk for aller-
gic rhinoconjunctivitis after preeclamptic pregnancies.
A possible causal relation between preeclampsia and
atopic disease in offspring could be linked to theses in late childhood in 586 Norwegian children according to
l preeclampsia
Final analysisb)
Likelihood-
ratio-
n Mild/moderate
preeclampsia
Severe
preeclampsia
Likelihood-
ratio
p
OR 95% CI OR 95% CI
p
0.268 586 1.25 (0.79, 1.97) 2.23 (1.20, 4.17) 0.046
0.914 ____
0.878 ____
0.138 ____
0.015 347 1.60 (0.88, 2.91) 4.05 (1.62, 10.1) 0.010d)
0.802 ____
8 years (girls) and 11.8 years (boys), FU2 second follow-up at the age of 12.8 years
aesarean section, maternal smoking during pregnancy, gestational age in weeks,
yses include the covariates gender and maternal asthma as default.
itized children.
d maternal asthma. No significant interaction effects were found in final analyses.
Table 4 Summary of linear regression analyses of lung
function in late childhood in 395 Norwegian children
according to mother’s preeclampsia status
Effects of maternal preeclampsia
Fully adjusteda)
n Mild/moderate
preeclampsia
Severe preeclampsia
Outcome
variable
b 95% CI p b 95% CI p
FEV1% 381 0.57 (−1.86, 2.99) 0.647 1.27 (−2.95, 5.49) 0.555
FVC% 381 −1.47 (−4.36, 1.42) 0.317 −2.24 (−7.28, 2.79) 0.381
FEV1/FVC 381 1.28 (−0.35, 2.92) 0.124 2.79 (−0.06, 5.64) 0.055
Abbreviations: FEV1% forced expiratory volume in first second predicted,
FVC% Forced vital capacity predicted, FEV1/FVC Ratio of actual FEV1 over FVC,
n number of participants, b regression coefficient, CI confidence interval,
a)Adjusted for gender, birth weight z-score adjusted for gestational age,
being firstborn, Caesarean section, maternal age, maternal smoking during
pregnancy, gestational age in weeks, maternal body mass index (kg/m2)
and maternal asthma.
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the tendency for preeclampsia to skew the cytokine pro-
file of the mother towards an increased Th1/Th2 ratio is
reflected in the cytokine pattern of the offspring during
pregnancy and early life, it could potentially protect the
child from the development of Th2 driven atopic disease
[6,22]. However, preeclampsia is a complex inflammatory
condition characterised by a variety of pro-inflammatory
cytokines beyond the Th1 type of cytokines [10,23]. Pro-
inflammatory cytokines, chemokines and adhesion mol-
ecules appear to be increased in maternal circulation
during preeclampsia [13], and could potentially initiate
the development of immunological conditions in the
foetus, such as atopic sensitization or diseases [6].
The association between preeclampsia and atopy could
be due to shared genetic or environmental factors in
pregnancy. Preeclampsia is more common in nulliparous
[24] and pregnancies with a male foetus [25], and atopic
disease is more common in first-born-children [26] and
boys up to adolescence [27]. According to the hygiene
hypothesis, the birth order effect on atopy may be ex-
plained by a reduced tendency for Th2 deviation due to
greater exposure to pathogens from older siblings [28].
However, recent studies have demonstrated a birth order
effect on cord blood IgE and food allergy in very early
life, suggesting a prenatal origin of this effect [29,30].
Our analyses were controlled for birth order, suggesting
that preeclampsia may be a risk factor for atopy in the
offspring unrelated to birth order. However, as this is an
observational study, the possibility of residual confound-
ing cannot be excluded.
Finally, maternal conditions prior to pregnancy could
increase the risk for both preeclampsia and atopic dis-
ease in offspring. Maternal asthma has been shown as arisk factor for preeclampsia [31]. To our knowledge, no
studies have shown any association between maternal al-
lergy and preeclampsia.
There was a trend of an increased risk of atopic disease
in the child by an increasing severity of the maternal pre-
eclampsia. Moreover, preeclampsia was not associated
with low level allergic sensitization, asthma or atopic
dermatitis. Low level allergic sensitization may be unspe-
cific and less related to clinical atopic disease compared to
higher levels of sensitization [32]. The pathophysiology of
asthma and atopic dermatitis is more multifactorial than
the specific allergy driven pathophysiology of rhinocon-
junctivitis. Our results may therefore suggest that the
association between severe preeclampsia and atopic
disease in offspring is related to specific Th2-mediated
mechanisms [29].
Preeclampsia, asthma, wheezing and lung function
Some studies have shown an association between differ-
ent complications of pregnancy and asthma in offspring,
but preeclampsia was not shown to be a risk factor in
these studies [12,33]. In a large population-based study
using a questionnaire, an association between maternal
preeclampsia and wheezing in the offspring was shown
[34]. A possible explanation for this association could be
that hypertension in pregnancy is related to fetal growth
restriction and hence altered airway function [35]. Our
results do not contradict this. Although we could not
find any association between preeclampsia and asthma
ever, current asthma or lung function in late childhood,
we did not investigate wheezing disorders in the first
years of life. However, the present study had a longer
follow-up than in the studies mentioned above, and may
therefore be better suited to study any long time effect
of preeclampsia on asthma and lung function in late
childhood.
One limitation of the study is the rather low rate of
participation, especially in FU2. It is not known whether
there was a difference in prevalence of asthma or atopy
between those who consented and those who didn’t con-
sent to overall follow-up. Especially for the outcomes of
asthma, there was a rather low response rate which in-
creases the risk of a type 2 error. Furthermore, children
who participated in FU1 but not in FU2 had a higher
BMI and more atopic dermatitis. This may have biased
our results, as both overweight and atopic dermatitis
may be associated with allergic sensitization and other
atopic disease.
Another limitation may be that that allergic rhinocon-
junctivitis, asthma and atopic dermatitis were defined only
by questionnaire. However, allergic sensitization was
found in 94.4% of children diagnosed with rhinoconjuncti-
vitis, suggesting a high degree of diagnostic accuracy.
Some children reported allergic rhinoconjunctivitis
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studies and does not rule out allergic rhinoconjunctivitis
[36]. Due to study design, allergic rhinoconjunctivitis and
allergic sensitization were assessed at two different
ages. However, this should not affect that independent
associations were found between preeclampsia preg-
nancies and allergic rhinoconjunctivitis and allergic
sensitization respectively.
In the multivariate analyses we included a set of vari-
ables possibly influencing the outcomes. The covariates
gestational age, birthweight z-score and caesarean sec-
tion could be considered as intermediate variables be-
tween preeclampsia and the outcomes, but may also be
independent risk factors for subsequent allergy and
atopic disease and were therefore included as covariates
in the analyses. Given the lack of complete ascertain-
ment of causal links, one cannot exclude the possibility
of collider bias and therefore biased associations be-
tween exposures and outcomes [37].
The only data on family atopy available were on ma-
ternal and paternal asthma. Paternal asthma was not
considered to be a possible confounder for the relation-
ship between maternal preeclampsia and subsequent
atopy, asthma or lung function in offspring and not in-
cluded as a covariate.
Conclusion
The results of this study suggest that severe maternal pre-
eclampsia may be associated with allergic sensitization and
allergic rhinoconjunctivitis in late childhood. This empha-
sizes the possible early origin of atopic disease, but larger
studies are needed to further explore the role of pre-
eclampsia in the development of atopic disease. No other
significant associations between maternal preeclampsia
and atopic dermatitis, asthma or lung function were found.
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